Therefore, it is assumed that ALT activity is not a biomarker of NAFLD or non-alcoholic steatohepatitis (NASH) and has no diagnostic significance in NASH or liver fibrosis. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.